title: Mitochondrial mitophagic mechanisms of myocardial matrix metabolism and remodelling.
abstract: High levels of homocysteine (Hcy), known as hyperhomocysteinmia (HHcy), are correlated with an increase in extracellular matrix remodelling (ECM) via the matrix metalloproteinases (MMPs) and plasminogen/plasmin system. This results in an increase deposition of collagen that leads to endothelial-myocyte (EM) and myocyte-myocyte (MM) uncoupling; the physiological consequences are a plethora of cardiovascular pathologies. Homocysteine-induced increase in intracellular and mitochondrial Ca(2+) plays an important role in increasing reactive oxygen species (ROS) within mitochondria and instigating mitophagy within the cell. This occurs via several Hcy-mitigated processes: agonizing N-methyl-d-aspartate receptor-1 (NMDA-R1), decreasing expression of peroxisome proliferator activator receptor (PPAR) [thereby increasing oxidation], impairing Ca(2+) handling via Na(+)/Ca(2+) exchanger (NCX1) and Sarco endoplasmic reticulum Ca(2+) ATPase (SERCA-2a). The end result is an increase in ROS that directly or indirectly lead to MMP activation within mitochondria or the cytoplasm. Hcy induces a mitochondrial permeability transition that allows MMPs to be released from mitochondria thereby metabolizing matrix and impairing cardiac function. Further work remains to be elucidated concerning the specific mitochondrial mitophagic mechanisms under which matrix metabolism and remodelling occurs. Moreover, the therapeutic implications of NMDA and PPAR ligands are some promise to patient.
authors.affiliation: Department of Physiology and Biophysics, School of Medicine, University of Louisville, Louisville, KY 40202, USA.
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Vacek
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Vacek
authors.forename: Suresh C
authors.initials: SC
authors.lastname: Tyagi
mesh_terms: D000818:Animals; D001343:Autophagy; D002118:Calcium / Q000378:metabolism; D005109:Extracellular Matrix / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology; D005341:Fibrinolysin / Q000378:metabolism; D006710:Homocysteine / Q000378:metabolism*; D006801:Humans; D020138:Hyperhomocysteinemia / Q000201:enzymology* / Q000473:pathology; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D051379:Mice; D008929:Mitochondria, Heart / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology; D009206:Myocardium / Q000201:enzymology* / Q000473:pathology; D032383:Myocytes, Cardiac / Q000201:enzymology* / Q000473:pathology; D018384:Oxidative Stress; D010539:Permeability; D047492:Peroxisome Proliferator-Activated Receptors / Q000378:metabolism; D010958:Plasminogen / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000378:metabolism; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases / Q000378:metabolism; D019831:Sodium-Calcium Exchanger / Q000378:metabolism; D020257:Ventricular Remodeling
chemical_list: D047492:Peroxisome Proliferator-Activated Receptors; D017382:Reactive Oxygen Species; D016194:Receptors, N-Methyl-D-Aspartate; D019831:Sodium-Calcium Exchanger; C110374:sodium-calcium exchanger 1; D006710:Homocysteine; D010958:Plasminogen; D005341:Fibrinolysin; D020782:Matrix Metalloproteinases; D053498:Sarcoplasmic Reticulum Calcium-Transporting ATPases; D002118:Calcium